doi: 10.1161/hs1201.099520
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2001;32:2828.)
© 2001 American Heart Association, Inc.
Original Contributions |
Should Stroke Subtype Influence Anticoagulation Decisions to Prevent Recurrence in Stroke Patients With Atrial Fibrillation?
From the Department of Medicine, Guy’s, King’s & St Thomas’ School of Medicine, King’s College, London, UK, and Queen Mary’s NHS Trust, Sidcup, Kent, UK (G.Y.).
Correspondence to Dr Andrew Evans, Department of Medicine, Guy’s, King’s & St Thomas’ School of Medicine, Denmark Hill Campus, Bessemer Rd, London, UK SE5 8PJ. E-mail andy.evans{at}kcl.ac.uk
Background and Purpose— Long-term anticoagulation is routinely used for secondary stroke prevention in atrial fibrillation, often regardless of stroke subtype. Although the role of warfarin in cardioembolic stroke is established, it may not prevent recurrence in other stroke subtypes, even in the presence of atrial fibrillation.
Methods— This was a 2-year, prospective, intervention study conducted in a district general hospital. Participants included 386 acute stroke patients with atrial fibrillation. Subjects were characterized for stroke subtype on clinical, neuroimaging, carotid ultrasonographic, and echocardiographic criteria. Eligible patients were treated with adjusted-dose warfarin (international normalized ratio, 2.0 to 3.0). Aspirin (75 to 300 mg/d) was used in patients with contraindications or those who refused anticoagulation. The main outcome measures were rate of recurrent stroke by subtype and major and minor bleeding complications.
Results— The aspirin group (n=172) was comparable to the warfarin group (n=214) in terms of age, sex, risk factors, and initial stroke subtype. The rate of recurrent stroke was higher (9.5% versus 4.9%, P<0.02) but that of major bleeding was lower (0.6% versus 2.5%, P<0.05) with aspirin. The increased stroke rate with aspirin was due predominantly to cardioembolic recurrence in patients presenting initially with cardioembolic stroke (8.4% versus 1.9%, P<0.01). The recurrence rate in aspirin-treated patients who presented with lacunar stroke and atrial fibrillation was similar to that seen in patients receiving warfarin (8.8% versus 8.9%).
Conclusions— In this cohort of stroke patients with atrial fibrillation, anticoagulation was superior to aspirin in preventing cardioembolic but not lacunar recurrence. Determination of stroke subtype may be important in anticoagulation decisions for secondary prevention, and further studies are required.
Key Words: anticoagulants • antiplatelet agents • lacunar infarction • stroke prevention • stroke, cardioembolic
This article has been cited by other articles:
 |
|
 |
|
  D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Liao, Z. Khalid, C. Scallan, C. Morillo, and M. O'Donnell Noninvasive Cardiac Monitoring for Detecting Paroxysmal Atrial Fibrillation or Flutter After Acute Ischemic Stroke: A Systematic Review Stroke, November 1, 2007; 38(11): 2935 - 2940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dudley and R. Fuller Comment on the WASPO study Age Ageing, September 1, 2007; 36(5): 598 - 599. [Full Text] [PDF]
|
|
|
|
 |
|
 The Stroke Risk in Atrial Fibrillation Working Gro Independent predictors of stroke in patients with atrial fibrillation: A systematic review Neurology, August 7, 2007; 69(6): 546 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. van Walraven, A. Jennings, N. Oake, D. Fergusson, and A. J. Forster Effect of Study Setting on Anticoagulation Control: A Systematic Review and Metaregression Chest, May 1, 2006; 129(5): 1155 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Arima, R. G. Hart, S. Colman, J. Chalmers, C. Anderson, A. Rodgers, M. Woodward, S. MacMahon, B. Neal, and for the PROGRESS Collaborative Group Perindopril-Based Blood Pressure-Lowering Reduces Major Vascular Events in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack Stroke, October 1, 2005; 36(10): 2164 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Sherman, S. G. Kim, B. S. Boop, S. D. Corley, J. P. DiMarco, R. G. Hart, L. J. Haywood, K. Hoyte, E. S. Kaufman, M. H. Kim, et al. Occurrence and Characteristics of Stroke Events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) Study Arch Intern Med, May 23, 2005; 165(10): 1185 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Singer, G. W. Albers, J. E. Dalen, A. S. Go, J. L. Halperin, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 429S - 456S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Hart, L. A. Pearce, and P. J. Koudstaal Transient Ischemic Attacks in Patients With Atrial Fibrillation: Implications for Secondary Prevention: The European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III Trial Stroke, April 1, 2004; 35(4): 948 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, E. M. Hylek, Y. Chang, K. A. Phillips, L. E. Henault, A. M. Capra, N. G. Jensvold, J. V. Selby, and D. E. Singer Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation: How Well Do Randomized Trials Translate Into Clinical Practice? JAMA, November 26, 2003; 290(20): 2685 - 2692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. I.H. Kwa, J. J. van der Sande, J. Stam, N. Tijmes, and J. L. Vrooland Retinal arterial changes correlate with cerebral small-vessel disease Neurology, November 26, 2002; 59(10): 1536 - 1540. [Abstract] [Full Text] [PDF]
|
|